ALX Oncology Holdings Inc.
ALXO

NASDAQ > Biotechnology
DCF:$0.12  |   P/E: -
$0.21(12.96%)
Change
Rating:
Price: $1.62 USD
Market Cap: $96.52M

...Loading ALXO Peers...





ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

    89 Employees

    CEO : Mr. Jason W. Lettmann

    Address : 323 Allerton Avenue, South San Francisco,CA, US, - 94080,

Key ExcutivesDesignation
Dr. Christopher Byrd J.D., Ph.D.General Counsel
Dr. Lin Yeong-Liang M.D., M.S.Senior Vice President of Drug Safety & Pharmacovigilance
Caitlyn DohertyManager of Investor Relations & Corporate Communications
Ms. Sue NaimSenior Vice President of Clinical Operations
Ms. Shelly Pinto CPAInterim Chief Financial Officer
Dr. Athanasios Tsiatis M.D.Senior Vice President of Clinical Development
Ms. Lisa SauerSenior Vice President of Regulatory Affairs & Quality Assurance
Mr. Jason W. LettmannChief Executive Officer & Director
Dr. Jaume Pons Ph.D.Founder, President, Chief Scientific Officer & Director
Dr. Michael Chang Ph.D.Vice President of Operations